Skip to main content
SpringerLink
Log in

Systemic-Onset Juvenile Idiopathic Arthritis

  • Chapter
  • First Online:
Periodic and Non-Periodic Fevers

Part of the book series: Rare Diseases of the Immune System ((RDIS))

  • 778 Accesses

Abstract

Systemic juvenile idiopathic arthritis (SJIA) is a disease of unknown etiology characterized by arthritis and systemic symptoms. Evidence shows that SJIA is probably not a single disease but a diverse group of clinically and genetically distinct illnesses. It is classified both as one of the Juvenile idiopathic arthritis (JIA) categories and also among the autoinflammatory diseases.

SJIA is probably the most severe forms of JIA, causing considerable morbidity and mortality. The macrophage activation syndrome (MAS), a form of secondary hemophagocytic lymphohistiocytosis (HLH), often appears in SJIA individuals and it still carries significant mortality.

The constant growth of knowledge about the pathogenesis and the development of target therapies with the different biological agents have transformed the course and prognosis of children with this entity.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Woo P. Anakinra treatment for systemic juvenile idiopathic arthritis and adult-onset Still disease. Ann Rheum Dis. 2008;67:281–2.

    Article  PubMed  Google Scholar 

  2. Masters SL, Simon A, Aksentijevich I, Kastner D. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. Annu Rev Immunol. 2009;27:621–68.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Mellins ED, Macaubas C, Grom AA. Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions. Nat Rev Rheumatol. 2011;7:416–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Hedrich CM, Tsokos GC. Bridging the gap between autoinflammation and autoimmunity. Clin Immunol. 2013;147:151–4.

    Article  CAS  PubMed  Google Scholar 

  5. Nigrovic PA. Autoinflammation and autoimmunity in systemic juvenile idiopathic arthritis. Proc Natl Acad Sci U S A. 2015;112:15785–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31:390–2.

    PubMed  Google Scholar 

  7. Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, et al. Preliminary criteria for classification of adult Still’s disease. J Rheumatol. 1992;19(3):424–30.

    CAS  PubMed  Google Scholar 

  8. Kumar S, Kunhiraman DS, Rajam L. Application of the Yamaguchi criteria for classification of “suspected” systemic juvenile idiopathic arthritis (sJIA). Pediatr Rheumatol. 2012;10:40.

    Article  Google Scholar 

  9. Vastert SJ, Nigrovic PA. Toward personalized treatment for systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 2018; https://doi.org/10.1002/art.40501.

    Article  Google Scholar 

  10. Eng SWM, Duong TT, Rosenberg AM, Morris Q, Yeung RS, REACCH OUT and BBOP Research Consortia. The biological basis of clinical heterogeneity in juvenile idiopathic arthritis. Arthritis Rheum. 2014;66:3463–75.

    Article  CAS  Google Scholar 

  11. Modesto C, Antón J, Rodriguez B, Bou R, Arnal C, Ros J, et al. Incidence and prevalence of juvenile idiopathic arthritis in Catalonia (Spain). Scand J Rheumatol. 2010;39:472–9.

    Article  CAS  PubMed  Google Scholar 

  12. Gurion R, Lehman TJ, Moorthy LN. Systemic arthritis in children: a review of clinical presentation and treatment. Int J Inflamm. 2012;2012:271569.

    Article  CAS  Google Scholar 

  13. Behrens EM, Beukelman T, Gallo L, Spangler J, Rosenkranz M, Arkachaisri T, et al. Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: data from the Pennsylvania Systemic Onset Juvenile Arthritis Registry. (PASOJAR). J Rheumatol. 2008;35:343–8.

    PubMed  Google Scholar 

  14. Feldman BM, Birdi N, Boone JE, Dent PB, Duffy CM, Ellsworth JE, et al. Seasonal onset of systemic-onset juvenile rheumatoid arthritis. J Pediatr. 1996;129(4):513–8.

    Article  CAS  PubMed  Google Scholar 

  15. Russo R, Katsicas MM. Patients with very early-onset systemic juvenile idiopathic arthritis exhibit more inflammatory features and a worse outcome. J Rheumatol. 2013;40:329–34.

    Article  CAS  PubMed  Google Scholar 

  16. Wallace CA, Levinson JE. Juvenile rheumatoid arthritis: outcome and treatment for the 1990s. Rheum Dis Clin North Am. 1991;17:891–905.

    CAS  PubMed  Google Scholar 

  17. Davies R, Southwood T, Kearsley-Fleet L, Lunt M, Baildam E, Beresford MW, et al. Mortality rates are increased in patients with systemic juvenile idiopathic arthritis. Arch Dis Child. 2017;102(2):206–7.

    Article  PubMed  Google Scholar 

  18. Hinze CH, Fall N, Thornton S, Mo JQ, Aronow BJ, Layh-Schmitt G, et al. Immature cell populations and an erythropoiesis gene-expression signature in systemic juvenile idiopathic arthritis: implications for pathogenesis. Arthritis Res Ther. 2010;12:R123.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  19. Fall N, Barnes M, Thornton S, Luyrink L, Olson J, Ilowite NT, et al. Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome. Arthritis Rheum. 2007;56:3793–804.

    Article  CAS  PubMed  Google Scholar 

  20. Omoyinmi E, Hamaoui R, Pesenacker A, Nistala K, Moncrieffe H, Ursu S, et al. Th1 and Th17 cell subpopulations are enriched in the peripheral blood of patients with systemic juvenile idiopathic arthritis. Rheumatology (Oxford). 2012;51(10):1881–6.

    Article  CAS  Google Scholar 

  21. Nigrovic PA. Is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis? Arthritis Rheum. 2014;66:1405–13.

    Article  CAS  Google Scholar 

  22. Kessel C, Lippitz A, Weinhage T, Hinze C, Wittkowski H, Holzinger D, et al. Proinflammatory cytokine environments can drive interleukin-17 overexpression by γ/δ T cells in systemic juvenile idiopathic arthritis. Arthritis Rheum. 2017;69:1480–94.

    Article  CAS  Google Scholar 

  23. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med. 2005;201:1479–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. de Jager W, Hoppenreijs EP, Wulffraat NM, Wedderburn LR, Kuis W, Prakken BJ. Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study. Ann Rheum Dis. 2007;66:589–98.

    Article  PubMed  CAS  Google Scholar 

  25. Frosch M, Roth J. New insights in systemic juvenile idiopathic arthritis-from pathophysiology to treatment. Rheumatology. 2008;47:121–5.

    Article  CAS  PubMed  Google Scholar 

  26. Shimizu M, Nakagishi Y, Kasai K, Yamasaki Y, Miyoshi M, Takei S, et al. Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: the diagnostic significance of interleukin-18 and interleukin-6. Cytokine. 2012;58:287–94.

    Article  CAS  PubMed  Google Scholar 

  27. Shimizu M, Nakagishi Y, Yachie A. Distinct subsets of patients with systemic juvenile idiopathic arthritis based on their cytokine profiles. Cytokine. 2013;61:345–8.

    Article  CAS  PubMed  Google Scholar 

  28. Muller K, Herner EB, Stagg A, Bendtzen K, Woo P. Inflammatory cytokines and cytokine antagonists in whole blood cultures of patients with systemic juvenile chronic arthritis. Br J Rheumatol. 1998;37:562–9.

    Article  CAS  PubMed  Google Scholar 

  29. Gattorno M, Piccini A, Lasiglie D, Tassi S, Brisca G, Carta S, et al. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2008;58:1505–15.

    Article  CAS  PubMed  Google Scholar 

  30. Allantaz F, Chaussabel D, Stichweh D, Bennett L, Allman W, Mejias A, et al. Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade. J Exp Med. 2007;204:2131–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Jelusić M, Lukić IK, Tambić-Bukovac L, Dubravcić K, Malcić I, Rudan I, et al. Interleukin-18 as a mediator of systemic juvenile idiopathic arthritis. Clin Rheumatol. 2007;26(8):1332–4.

    Article  PubMed  Google Scholar 

  32. Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat N, Horneff G, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2396–406.

    Article  CAS  PubMed  Google Scholar 

  33. Lotito AP, Campa A, Silva CA, Kiss MH, Mello SB. Interleukin 18 as a marker of disease activity and severity in patients with juvenile idiopathic arthritis. J Rheumatol. 2007;34:823–30.

    CAS  PubMed  Google Scholar 

  34. Shimizu M, Yokoyama T, Yamada K, Kaneda H, Wada H, Wada T, et al. Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis. Rheumatology (Oxford). 2010;49:1645–53.

    Article  CAS  Google Scholar 

  35. de Benedetti F, Massa M, Robbioni P, Ravelli A, Burgio GR, Martini A. Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum. 1991;34:1158–63.

    Article  PubMed  Google Scholar 

  36. Cazzola M, Ponchio L, de Benedetti F, Ravelli A, Rosti V, Beguin Y, et al. Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemic-onset juvenile chronic arthritis. Blood. 1996;87:4824–30.

    Article  CAS  PubMed  Google Scholar 

  37. de Benedetti F, Meazza C, Oliveri M, Pignatti P, Vivarelli M, Alonzi T, et al. Effect of IL-6 on IGF binding protein-3: a study in IL-6 transgenic mice and in patients with systemic juvenile idiopathic arthritis. Endocrinology. 2001;142:4818–26.

    Article  PubMed  Google Scholar 

  38. Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomized, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371:998–1006.

    Article  CAS  PubMed  Google Scholar 

  39. Raziuddin S, Bahabri S, al-Dalaan A, Siraj AK, al-Sedairy S. A mixed Th1/Th2 cell cytokine response predominates in systemic onset juvenile rheumatoid arthritis: immunoregulatory IL-10 function. Clin Immunol Immunopathol. 1998;86:192–8.

    Article  CAS  PubMed  Google Scholar 

  40. Pignatti P, Vivarelli M, Meazza C, Rizzolo MG, Martini A, De BF. Abnormal regulation of interleukin 6 in systemic juvenile idiopathic arthritis. J Rheumatol. 2001;28:1670–6.

    CAS  PubMed  Google Scholar 

  41. de Benedetti F, Alonzi T, Moretta A, Lazzaro D, Costa P, Poli V, et al. Interleukin-6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation. J Clin Invest. 1997;99:643–50.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Strippoli R, Carvello F, Scianaro R, Pasquale LD, Vivarelli M, Petrini S, et al. Amplification of the response to Toll-like receptor ligands by prolonged exposure to interleukin-6 in mice: implications for the pathogenesis of macrophage activation syndrome. Arthritis Rheum. 2012;64:1680–8.

    Article  CAS  PubMed  Google Scholar 

  43. Canna SW, Wrobel J, Chu N, Kreiger PA, Paessler M, Behrens EM. Interferon-gamma mediates anemia but is dispensable for fulminant toll-like receptor 9-induced macrophage activation syndrome and hemophagocytosis in mice. Arthritis Rheum. 2013;65:1764–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Avau A, Mitera T, Put S, Put K, Brisse E, Filtjens J, et al. Systemic juvenile idiopathic arthritis-like syndrome in mice following stimulation of the immune system with Freund’s complete adjuvant: regulation by interferon-gamma. Arthritis Rheum. 2014;66:1340–51.

    Article  CAS  Google Scholar 

  45. Bracaglia C, de Graaf K, Marafon DP, Guilhot F, Ferlin W, Prencipe G, et al. Elevated circulating levels of interferon-γ and interferon-γ-induced chemokines characterize patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Ann Rheum Dis. 2017;76:166–72.

    Article  CAS  PubMed  Google Scholar 

  46. Wouters CH, Ceuppens JL, Stevens EA. Different circulating lymphocyte profiles in patients with different subtypes of juvenile idiopathic arthritis. Clin Exp Rheumatol. 2002;20:239–48.

    CAS  PubMed  Google Scholar 

  47. Zhou J, Tang X, Ding Y, An Y, Zhao X. Natural killer cell activity and frequency of killer cell immunoglobulin-like receptors in children with different forms of juvenile idiopathic arthritis. Pediatr Allergy Immunol. 2013;24:691–6.

    Article  PubMed  Google Scholar 

  48. Grom AA, Villanueva J, Lee S, Goldmuntz EA, Passo MH, Filipovich A. Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome. J Pediatr. 2003;142:292–6.

    Article  CAS  PubMed  Google Scholar 

  49. Villanueva J, Lee S, Giannini EH, Graham TB, Passo MH, Filipovich A, et al. Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome. Arthritis Res Ther. 2005;7:R30–7.

    Article  CAS  PubMed  Google Scholar 

  50. Wulffraat NM, Rijkers GT, Elst E, Brooimans R, Kuis W. Reduced perforin expression in systemic juvenile idiopathic arthritis is restored by autologous stem-cell transplantation. Rheumatology (Oxford). 2003;42:375–9.

    Article  CAS  Google Scholar 

  51. Put K, Vandenhaute J, Avau A, et al. Inflammatory gene expression profile and defective interferon-γ and granzyme K in natural killer cells from systemic juvenile idiopathic arthritis patients. Arthritis Rheum. 2017;69:213–24.

    Article  CAS  Google Scholar 

  52. Brady J, Carotta S, Thong RP, Chan CJ, Hayakawa Y, Smyth MJ, et al. The interactions of multiple cytokines control NK cell maturation. J Immunol. 2010;185:6679–88.

    Article  CAS  PubMed  Google Scholar 

  53. Cifaldi L, Prencipe G, Caiello I, Bracaglia C, Locatelli F, de Benedetti F, et al. Inhibition of natural killer cell cytotoxicity by interleukin-6: implications for the pathogenesis of macrophage activation syndrome. Arthritis Rheum. 2015;67:3037–46.

    Article  CAS  Google Scholar 

  54. de Jager W, Vastert SJ, Beekman JM, Wulffraat NM, Kuis W, Coffer PJ, et al. Defective phosphorylation of interleukin-18 receptor b causes impaired natural killer cell function in systemic onset juvenile idiopathic arthritis. Arthritis Rheum. 2009;60:2782–93.

    Article  PubMed  CAS  Google Scholar 

  55. Macaubas C, Nguyen K, Deshpande C, Phillips C, Peck A, Lee T, et al. Distribution of circulating cells in systemic juvenile idiopathic arthritis across disease activity states. Clin Immunol. 2010;134:206–16.

    Article  CAS  PubMed  Google Scholar 

  56. Macaubas C, Nguyen KD, Peck A, Buckingham J, Deshpande C, Wong E, et al. Alternative activation in systemic juvenile idiopathic arthritis monocytes. Clin Immunol. 2012;142:362–72.

    Article  CAS  PubMed  Google Scholar 

  57. Macaubas C, Wong E, Zhang Y, Nguyen KD, Lee J, Milojevic D, et al. Altered signaling in systemic juvenile idiopathic arthritis monocytes. Clin Immunol. 2016;163:66–74.

    Article  CAS  PubMed  Google Scholar 

  58. Schulert GS, Fall N, Harley JB, Shen N, Lovell DJ, Thornton S, et al. Monocyte microRNA expression in active systemic juvenile idiopathic arthritis implicates microRNA-125a-5p in polarized monocyte phenotypes. Arthritis Rheum. 2016;68:2300–13.

    Article  CAS  Google Scholar 

  59. Cepika AM, Banchereau R, Segura E, Ohouo M, Cantarel B, Goller K, et al. A multidimensional blood stimulation assay reveals immune alterations underlying systemic juvenile idiopathic arthritis. J Exp Med. 2017;214:3449–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Frosch M, Vogl T, Seeliger S, Wulffraat N, Kuis W, Viemann D, et al. Expression of myeloid-related proteins 8 and 14 in systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum. 2003;48:2622–6.

    Article  CAS  PubMed  Google Scholar 

  61. Foell D, Wittkowski H, Hammerschmidt I, Wulffraat N, Schmeling H, Frosch M, et al. Monitoring neutrophil activation in juvenile rheumatoid arthritis by S100A12 serum concentrations. Arthritis Rheum. 2004;50:1286–95.

    Article  CAS  PubMed  Google Scholar 

  62. Foell D, Roth J. Proinflammatory S100 proteins in arthritis and autoimmune disease. Arthritis Rheum. 2004;50:3762–71.

    Article  CAS  PubMed  Google Scholar 

  63. Ombrello MJ, Remmers EF, Tachmazidou I, Grom A, Foell D, Haas JP, et al. HLA-DRB1∗11 and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis. Proc Natl Acad Sci U S A. 2015;112:15970–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Hinks A, Bowes J, Cobb J, Ainsworth HC, Marion MC, Comeau ME, et al. Fine-mapping the MHC locus in juvenile idiopathic arthritis (JIA) reveals genetic heterogeneity corresponding to distinct adult inflammatory arthritic diseases. Ann Rheum Dis. 2017;76:765–72.

    Article  CAS  PubMed  Google Scholar 

  65. Stock CJ, Ogilvie EM, Samuel JM, Fife M, Lewis CM, Woo P. Comprehensive association study of genetic variants in the IL-1 gene family in systemic juvenile idiopathic arthritis. Genes Immun. 2008;9:349–57.

    Article  CAS  PubMed  Google Scholar 

  66. de Benedetti F, Meazza C, Vivarelli M, Rossi F, Pistorio A, Lamb R, et al. Functional and prognostic relevance of the -173 polymorphism of the macrophage migration inhibitory factor gene in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2003;48:1398–407.

    Article  PubMed  CAS  Google Scholar 

  67. Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest. 1998;102:1369–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Ogilvie EM, Fife MS, Thompson SD, Twine N, Tsoras M, Moroldo M, et al. The -174G allele of the interleukin-6 gene confers susceptibility to systemic arthritis in children. Arthritis Rheum. 2003;48:3202–6.

    Article  CAS  PubMed  Google Scholar 

  69. Donn RP, Barrett JH, Farhan A, Stopford A, Pepper L, Shelley E, et al. Cytokine gene polymorphisms and susceptibility to juvenile idiopathic arthritis. British Paediatric Rheumatology Study Group. Arthritis Rheum. 2001;44:802–10.

    Article  CAS  PubMed  Google Scholar 

  70. Donn RP, Shelley E, Ollier WE, Thomson W, British Paediatric Rheumatology Study Group, et al. A novel 5′-flanking region polymorphism of macrophage migration inhibitory factor is associated with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2001;44:1782–5.

    Article  CAS  PubMed  Google Scholar 

  71. Fife MS, Gutierrez A, Ogilvie EM, Stock CJ, Samuel JM, Thomson W, et al. Novel IL10 gene family associations with systemic juvenile idiopathic arthritis. Arthritis Res Ther. 2006;8:R148.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  72. Moller JC, Paul D, Ganser G, Range U, Gahr M, Kelsch R, et al. IL10 promoter polymorphisms are associated with systemic onset juvenile idiopathic arthritis (SoJIA). Clin Exp Rheumatol. 2010;28:912–8.

    CAS  PubMed  Google Scholar 

  73. Yanagimachi M, Goto H, Miyamae T, Kadota K, Imagawa T, Mori M, et al. Association of IRF5 polymorphisms with susceptibility to hemophagocytic lymphohistiocytosis in children. J Clin Immunol. 2011;31:946–51.

    Article  PubMed  Google Scholar 

  74. Ayaz NA, Ozen S, Bilginer Y, Ergüven M, Taşkiran E, Yilmaz E, et al. MEFV mutations in systemic onset juvenile idiopathic arthritis. Rheumatology. 2009;48:23–5.

    Article  CAS  PubMed  Google Scholar 

  75. Cantarini L, Lucherini OM, Simonini G, Galeazzi M, Baldari CT, Cimaz R. Systemic-onset juvenile idiopathic arthritis complicated by early onset amyloidosis in a patient carrying a mutation in the MEFV gene. Rheumatol Int. 2012;32:465–7.

    Article  PubMed  Google Scholar 

  76. Tadaki H, Saitsu H, Nishimura-Tadaki A, Imagawa T, Kikuchi M, Hara R, et al. De novo 19q13.42 duplications involving NLRP gene cluster in a patient with systemic-onset juvenile idiopathic arthritis. J Human Genet. 2011;56:343–7.

    Article  CAS  Google Scholar 

  77. Lamb R, Thomson W, Ogilvie E, Donn R. Positive association of SLC26A2 gene polymorphisms with susceptibility to systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2007;56:1286–91.

    Article  CAS  PubMed  Google Scholar 

  78. Hazen MM, Woodward AL, Hofmann I, Degar BA, Grom A, Filipovich AH, et al. Mutations of the hemophagocytic lymphohistiocytosis-associated gene UNC13D in a patient with systemic juvenile idiopathic arthritis. Arthritis Rheum. 2008;58:567–70.

    Article  CAS  PubMed  Google Scholar 

  79. Vastert SJ, van Wijk R, D’Urbano LE, de Vooght KM, de Jager W, Ravelli A, et al. Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis. Rheumatology (Oxford). 2010;49:441–9.

    Article  CAS  Google Scholar 

  80. Zhang K, Biroschak J, Glass DN, et al. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis is associated with MUNC13-4 polymorphisms. Arthritis Rheum. 2008;58:2892–6.

    Article  PubMed  PubMed Central  Google Scholar 

  81. Kaufman KM, Linghu B, Szustakowski JD, Husami A, Yang F, Zhang K, et al. Whole-exome sequencing reveals overlap between macrophage activation syndrome in systemic juvenile idiopathic arthritis and familial hemophagocytic lymphohistiocytosis. Arthritis Rheum. 2014;66:3486–95.

    Article  CAS  Google Scholar 

  82. Wakil SM, Monies DM, Abouelhoda M, Al-Tassan N, Al-Dusery H, Naim EA, et al. Association of a mutation in LACC1 with a monogenic form of systemic juvenile idiopathic arthritis. Arthritis Rheum. 2015;67:288–95.

    Article  CAS  Google Scholar 

  83. Kallinich T, Thorworth A, von Stuckrad SL, et al. Juvenile arthritis caused by a novel FAMIN (LACC1) mutation in two children with systemic and extended oligoarticular course. Pediatr Rheumatol. 2016;14:63.

    Article  Google Scholar 

  84. Gohar F, Kessel C, Lavric M, Holzinger D, Foell D. Review of biomarkers in systemic juvenile idiopathic arthritis: helpful tools or just playing tricks? Arthritis Res Ther. 2016;18:163.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  85. Wittkowski H, Frosch M, Wulffraat N, Goldbach-Mansky R, et al. S100A12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of unknown origin. Arthritis Rheum. 2008;58:3924–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Dong S, Bout-Tabaku S, Texter K, Jaggi P. Diagnosis of systemic-onset juvenile idiopathic arthritis after treatment for presumed Kawasaki disease. J Pediatr. 2015;166(5):1283–8.

    Article  PubMed  Google Scholar 

  87. Calabro JJ, Marchesano JM. Fever associated with juvenile rheumatoid arthritis. N Engl J Med. 1967;276(1):11–8.

    Article  CAS  PubMed  Google Scholar 

  88. Calabro JJ, Holgerson WB, Sonpal GM, Khoury MI. Juvenile rheumatoid arthritis: a general review and report of 100 patients observed for 15 years. Semin Arthritis Rheum. 1976;5(3):257–98.

    Article  CAS  PubMed  Google Scholar 

  89. Roth J, Scheer I, Kraft S, Keitzer R, Riebel T. Uncommon synovial cysts in children. Eur J Pediatr. 2006;165(3):178–81.

    Article  PubMed  Google Scholar 

  90. Schneider R, Laxer RM. Systemic onset juvenile rheumatoid arthritis. Baillieres Clin Rheumatol. 1998;12:245–71.

    Article  CAS  PubMed  Google Scholar 

  91. Frosch M, Metze D, Foell D, Vogl T, Sorg C, Sunderkötter C, et al. Early activation of cutaneous vessels and epithelial cells is characteristic of acute systemic onset juvenile idiopathic arthritis. Exp Dermatol. 2005;14:259–65.

    Article  PubMed  Google Scholar 

  92. Bywaters EG, Isdale IC. The rash of rheumatoid arthritis and Still’s disease. Q J Med. 1956;25(99):377–87.

    CAS  PubMed  Google Scholar 

  93. Shishov M, Henrickson M, Burgos-Vargas R, Rubio-Pérez N, Baca V, Romero-Feregrino R, et al. Systemic features and early prognostic factors in Hispanic and non-Hispanic children from the United States of America and Mexico with systemic juvenile idiopathic arthritis. Clin Exp Rheumatol. 2007;25(6):907–14.

    CAS  PubMed  Google Scholar 

  94. Ramanan AV, Wynn RF, Kelsey A, Baildam EM. Systemic juvenile idiopathic arthritis, Kikuchi’s disease and haemophagocytic lymphohistiocytosis - is there a link? Case report and literature review. Rheumatology (Oxford). 2003;42:596–8.

    Article  CAS  Google Scholar 

  95. Ambrósio C, Abreu P, Alexandre M, Malcata A. Lymphoedema in systemic juvenile arthritis: a rare extra-articular feature. Acta Reumatol Port. 2008;33(4):457–9.

    PubMed  Google Scholar 

  96. Parvez N, Carpenter JL. Cardiac tamponade in Still disease: a review of the literature. South Med J. 2009;102(8):832–7.

    Article  PubMed  Google Scholar 

  97. Tabak F, Tanverdi M, Ozaras R, Mert A, Tartan Z, Ozturk R, et al. Neutrophilic pleocytosis in cerebrospinal fluid: adult-onset Still’s disease. Intern Med. 2003;42:1039–41.

    Article  PubMed  Google Scholar 

  98. Heyd J, Glaser J. Early occurrence of aortic valve regurgitation in a youth with systemic-onset juvenile rheumatoid arthritis. Am J Med. 1990;89:123–4.

    Article  CAS  PubMed  Google Scholar 

  99. Kimura Y, Weiss JE, Haroldson KL, Lee T, Punaro M, Oliveira S, et al. Pulmonary hypertension and other potentially fatal pulmonary complications in systemic juvenile idiopathic arthritis. Arthritis Care Res. 2013;65(5):745–52.

    Article  CAS  Google Scholar 

  100. Wang FM, Wertenbaker C, Behrens MM, Jacobs JC. Acquired Brown’s syndrome in children with juvenile rheumatoid arthritis. Ophthalmology. 1984;91:23–6.

    Article  CAS  PubMed  Google Scholar 

  101. Avcin T, Silverman ED, Forte V, Schneider R. Nasal septal perforation: a novel clinical manifestation of systemic juvenile idiopathic arthritis/adult onset Still’s disease. J Rheumatol. 2005;32:2429–31.

    PubMed  Google Scholar 

  102. Limenis E, Feldman BM, Achonu C, Batthish M, Lang B, Mclimont M, et al. Proposed core set of items for measuring disease activity in systemic juvenile idiopathic arthritis. J Rheumatol. 2018;45(1):115–21.

    Article  PubMed  Google Scholar 

  103. Hügle B, Hinze C, Lainka E, Fischer N, Haas JP. Development of positive antinuclear antibodies and rheumatoid factor in systemic juvenile idiopathic arthritis points toward an autoimmune phenotype later in the disease course. Pediatr Rheumatol Online J. 2014;12:28.

    Article  PubMed  PubMed Central  Google Scholar 

  104. Berntson L, Nordal E, Fasth A, Aalto K, Herlin T, Nielsen S, et al. Anti-type II collagen antibodies, anti-CCP, IgA RF and IgM RF are associated with joint damage, assessed eight years after onset of juvenile idiopathic arthritis (JIA). Pediatr Rheumatol Online J. 2014;12:22.

    Article  PubMed  PubMed Central  Google Scholar 

  105. Pang SY, Liu HY, Huang YJ, Liu YF, Dai YM, Zeng P, et al. Diagnostic performance of anti-citrullinated protein/peptide antibodies in juvenile idiopathic arthritis. Genet Mol Res. 2016;15(2). https://doi.org/10.4238/gmr.15028641.

  106. Ferucci ED, Majka DS, Parrish LA, Moroldo MB, Ryan M, Passo M, et al. Antibodies against cyclic citrullinated peptide are associated with HLA-DR4 in simplex and multiplex polyarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum. 2005;52:239–46.

    Article  CAS  PubMed  Google Scholar 

  107. Ling XB, Park JL, Carroll T, Nguyen KD, Lau K, Macaubas C, et al. Plasma profiles in active systemic juvenile idiopathic arthritis: biomarkers and biological implications. Proteomics. 2010;10(24):4415–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  108. Gerss J, Roth J, Holzinger D, Ruperto N, Wittkowski H, Frosch M, et al. Phagocyte-specific S100 proteins and high-sensitivity C reactive protein as biomarkers for a risk-adapted treatment to maintain remission in juvenile idiopathic arthritis: a comparative study. Ann Rheum Dis. 2012;71:1991–7.

    Article  CAS  PubMed  Google Scholar 

  109. Holzinger D, Frosch M, Kastrup A, Prince FH, Otten MH, Van Suijlekom-Smit LW, et al. The Toll-like receptor 4 agonist MRP8/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis. Ann Rheum Dis. 2012;71:974–80.

    Article  CAS  PubMed  Google Scholar 

  110. Shenoi S, Ou JN, Ni C, Macaubas C, Gersuk VH, Wallace CA, et al. Comparison of biomarkers for systemic juvenile idiopathic arthritis. Pediatr Res. 2015;78:554–9.

    Article  CAS  PubMed  Google Scholar 

  111. Rothmund F, Gerss J, Ruperto N, Däbritz J, Wittkowski H, Frosch M, et al. Validation of relapse risk biomarkers for routine use in patients with juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2014;66(6):949–55.

    Article  CAS  Google Scholar 

  112. van den Ham HJ, de Jager W, Bijlsma JW, Prakken BJ, de Boer RJ. Differential cytokine profiles in juvenile idiopathic arthritis subtypes revealed by cluster analysis. Rheumatology (Oxford). 2009;48(8):899–905.

    Article  CAS  Google Scholar 

  113. Miyamae T, Malehorn DE, Lemster B, Mori M, Imagawa T, Yokota S, et al. Serum protein profile in systemic-onset juvenile idiopathic arthritis differentiates response versus non response to therapy. Arthritis Res Ther. 2005;7:R746–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  114. Smith EM, Jorgensen AL, Midgley A, Oni L, Goilav B, Putterman C, et al. International validation of a urinary biomarker panel for identification of active lupus nephritis in children. Pediatr Nephrol. 2017;32(2):283–95.

    Article  PubMed  Google Scholar 

  115. Ozawa R, Inaba Y, Mori M, Hara R, Kikuchi M, Higuchi R, et al. Definitive differences in laboratory and radiological characteristics between two subtypes of juvenile idiopathic arthritis: systemic arthritis and polyarthritis. Mod Rheumatol. 2012;22(4):558–64.

    Article  CAS  PubMed  Google Scholar 

  116. Solari N, Viola S, Pistorio A, Magni-Manzoni S, Vitale R, Ruperto N, et al. Assessing current outcomes of juvenile idiopathic arthritis: a cross-sectional study in a tertiary center sample. Arthritis Rheum. 2008;15(59):1571–9.

    Article  Google Scholar 

  117. Shelmerdine SC, Di Paolo PL, Tanturri de Horatio L, Malattia C, Magni-Manzoni S, et al. Imaging of the hip in juvenile idiopathic arthritis. Pediatr Radiol. 2018;48(6):811–7.

    Article  PubMed  Google Scholar 

  118. Lang BA, Schneider R, Reilly BJ, Silverman ED, Laxer RM. Radiologic features of systemic onset juvenile rheumatoid arthritis. J Rheumatol. 1995 Jan;22(1):168–73.

    CAS  PubMed  Google Scholar 

  119. Sudoł-Szopińska I, Matuszewska G, Gietka P, Płaza M, Walentowska-Janowicz M. Imaging of juvenile idiopathic arthritis. Part I: Clinical classifications and radiographs. J Ultrason. 2016;16:225–36.

    Article  PubMed  PubMed Central  Google Scholar 

  120. Bowyer SL, Roettcher PA, Higgins GC, Adams B, Myers LK, Wallace C, et al. Health status of patients with juvenile rheumatoid arthritis at 1 and 5 years after diagnosis. J Rheumatol. 2003;30(2):394–400.

    PubMed  Google Scholar 

  121. Simon D, Lucidarme N, Prieur AM, Ruiz JC, Czernichow P. Treatment of growth failure in juvenile chronic arthritis. Horm Res. 2002;58(Suppl 1):28–32.

    CAS  PubMed  Google Scholar 

  122. Simon D. Management of growth retardation in juvenile idiopathic arthritis. Horm Res. 2007;68(Suppl 5):122–5.

    PubMed  Google Scholar 

  123. Yilmaz M, Kendirli SG, Altintas DU, Karakoc GB, Inal A, Kilic M. Juvenile idiopathic arthritis profile in Turkish children. Pediatr Int. 2008;50(2):154–8.

    Article  PubMed  Google Scholar 

  124. Packham JC, Hall MA. Long-term follow-up of 246 adults with juvenile idiopathic arthritis: functional outcome. Rheumatology (Oxford). 2002;41:1428–35.

    Article  CAS  Google Scholar 

  125. Saha A, Chopra Y, Theis JD, Vrana JA, Sethi S. AA amyloidosis associated with systemic-onset juvenile idiopathic arthritis. Am J Kidney Dis. 2013;62:834–8.

    Article  PubMed  Google Scholar 

  126. Murray KJ, Boyle RJ, Woo P. Pathological fractures and osteoporosis in a cohort of 103 systemic onset juvenile idiopathic arthritis patients. Arthritis Rheum. 2000;43:S119.

    Google Scholar 

  127. Stagi S, Masi L, Capannini S, Cimaz R, Tonini G, Matucci-Cerinic M, et al. Cross-sectional and longitudinal evaluation of bone mass in children and young adults with juvenile idiopathic arthritis: the role of bone mass determinants in a large cohort of patients. J Rheumatol. 2010;37:1935–43.

    Article  PubMed  Google Scholar 

  128. Rodd C, Lang B, Ramsay T, Alos N, Huber AM, Cabral DA, et al. Incident vertebral fractures among children with rheumatic disorders 12 months after glucocorticoid initiation: a national observational study. Arthritis Care Res (Hoboken). 2012;64:122–31.

    Article  Google Scholar 

  129. Lien G, Flatø B, Haugen M, Vinje O, Sørskaar D, Dale K. Frequency of osteopenia in adolescents with early-onset juvenile idiopathic arthritis: a long-term outcome study of one hundred five patients. Arthritis Rheum. 2003;48:2214–23.

    Article  PubMed  Google Scholar 

  130. Behrens EM, Beukelman T, Paessler M, Cron RQ. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol. 2007;34:1133–8.

    PubMed  Google Scholar 

  131. Minoia F, Davì S, Horne A, Demirkaya E, Bovis F, Li C, Lehmberg K, et al. Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients. Arthritis Rheum. 2014;66:3160–9.

    Article  Google Scholar 

  132. Schulert GS, Grom AA. Pathogenesis of macrophage activation syndrome and potential for cytokine-directed therapies. Annu Rev Med. 2015;66:18.1–18.15.

    Article  CAS  Google Scholar 

  133. Sawhney S, Woo P, Murray KJ. Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch Dis Child. 2001;85(5):421–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  134. Stéphan JL, Koné-Paut I, Galambrun C, Mouy R, Bader-Meunier B, Prieur AM. Reactive haemophagocytic syndrome in children with inflammatory disorders. A retrospective study of 24 patients. Rheumatology (Oxford). 2001;40:1285–92.

    Article  Google Scholar 

  135. Russo RAG, Rosenzweig S, Katsicas MM. Hepatitis A-associated macrophage activation syndrome in children with systemic juvenile idiopathic arthritis: report of 2 cases. J Rheumatol. 2008;35:166–8.

    PubMed  Google Scholar 

  136. Ravelli A, Minoia F, Davi S, Horne A, Bovis F, Pistorio A, et al. Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. RMD Open. 2016;2:e000161.

    Article  PubMed  PubMed Central  Google Scholar 

  137. Bleesing J, Prada A, Siegel DM, Villanueva J, Olson J, Ilowite NT, et al. The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor α-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. Arthritis Rheum. 2007;56:965–71.

    Article  CAS  PubMed  Google Scholar 

  138. Ravelli A, Magni-Manzoni S, Pistorio A, Besana C, Foti T, Ruperto N, et al. Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Pediatr. 2005;146:598–604.

    Article  PubMed  Google Scholar 

  139. Ravelli A, Minoia F, Davi S, Horne A, Bovis F, Pistorio A, et al. 2016 Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Ann Rheum Dis. 2016;75:481–9.

    Article  CAS  PubMed  Google Scholar 

  140. Schulert GS, Minoia F, Bohnsack J, Cron RQ, Hashad S, Koné-Paut I, et al. Biologic therapy modifies clinical and laboratory features of macrophage activation syndrome associated with systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2018;70(3):409–19.

    Article  CAS  Google Scholar 

  141. Minoia F, Davi S, Horne A, Bovis F, Demirkaya E, Akikusa J, et al. Dissecting the heterogeneity of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Rheumatol. 2015;42:994–1001.

    Article  PubMed  Google Scholar 

  142. Kimura Y, Fieldston E, Devries-Vandervlugt B, Li S, Imundo L, et al. High dose, alternate day corticosteroids for systemic onset juvenile rheumatoid arthritis. J Rheumatol. 2000;27:2018–24.

    CAS  PubMed  Google Scholar 

  143. Nigrovic P, Mannion M, Prince FHM, Zeft A, Rabinovich CE, van Rossum MA, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis. Arthritis Rheum. 2011;63:545–55.

    Article  CAS  PubMed  Google Scholar 

  144. Hedrich CM, Bruck N, Fiebig B, Gahr M. Anakinra: a safe and effective first-line treatment in systemic onset juvenile idiopathic arthritis (SoJIA). Rheumatol Int. 2012;32:3525–30.

    Article  CAS  PubMed  Google Scholar 

  145. DeWitt EM, Kimura Y, Beukelman T, Nigrovic PA, Onel K, Prahalad S, et al. Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Arthritis Care Res. 2012;64:1001–10.

    CAS  Google Scholar 

  146. Vastert SJ, de Jager W, Noordman BJ, Holzinger D, Kuis W, Prakken BJ, et al. Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis. Arthritis Rheum. 2014;66:1034–43.

    Article  CAS  Google Scholar 

  147. Ilowite NT, Sandborg CI, Feldman BM, Grom A, Schanberg LE, Giannini EH, et al. Algorithm development for corticosteroid management in systemic juvenile idiopathic arthritis trial using consensus methodology. Pediatr Rheumatol. 2012;10:31.

    Article  Google Scholar 

  148. Woo P, Southwood TR, Prieur A-M, Doré CJ, Grainger J, David J, et al. Randomized, placebo-controlled crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum. 2000;43:1849–57.

    Article  CAS  PubMed  Google Scholar 

  149. Lehman TJ, Schechter SJ, Sundel RP, Oliveira SK, Huttenlocher A, Onel KB, et al. Thalidomide for severe systemic onset juvenile rheumatoid arthritis: a multicenter study. J Pediatr. 2004;145:856–7.

    Article  CAS  PubMed  Google Scholar 

  150. ten Cate R, Nibbering PH, Bredius RG. Therapy-refractory systemic juvenile idiopathic arthritis successfully treated with statins. Rheumatology (Oxford). 2004;43:934–5.

    Article  Google Scholar 

  151. Silverman ED, Laxer RM, Greenwald M, Gelfand E, Shore A, Stein LD, et al. Intravenous gamma globulin therapy in systemic juvenile rheumatoid arthritis. Arthritis Rheum. 1990;33(7):1015–22.

    Article  CAS  PubMed  Google Scholar 

  152. Silverman ED, Cawkwell GD, Lovell DJ, Laxer RM, Lehman TJ, Passo MH, et al. Intravenous immunoglobulin in the treatment of systemic juvenile rheumatoid arthritis: a randomized placebo-controlled trial. Pediatric Rheumatology Collaborative Study Group. J Rheumatol. 1994;21(12):2353–8.

    CAS  PubMed  Google Scholar 

  153. Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med. 2000;16(342):763–9.

    Article  Google Scholar 

  154. Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Pérez N, Silva CA, et al. Abatacept in children with juvenile idiopathic arthritis: a randomized, double-blind, placebo-controlled withdrawal trial. Lancet. 2008;372:383–91.

    Article  CAS  PubMed  Google Scholar 

  155. Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008;359:810–20.

    Article  CAS  PubMed  Google Scholar 

  156. Russo RAG, Katsicas MM, Zelazko M. Etanercept in systemic juvenile idiopathic arthritis. Clin Exp Rheumatol. 2002;20:723–6.

    CAS  PubMed  Google Scholar 

  157. Quartier P, Taupin P, Bordeaut F, Lemelle I, Pillet P, Bost M, et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum. 2003;48:1093–101.

    Article  CAS  PubMed  Google Scholar 

  158. Horneff G, Schmeling H, Biederman T, Foeldvari I, Ganser G, Girschick HJ, et al. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis. 2004;63:1638–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  159. Kimura Y, Pinho P, Walco G, Higgins G, Hummell D, Szer I, et al. Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis. J Rheumatol. 2005;32:935–42.

    CAS  PubMed  Google Scholar 

  160. Katsicas MM, Russo RAG. Use of adalimumab in patients with juvenile idiopathic arthritis refractory to etanercept and/or infliximab. Clin Rheumatol. 2009;28:985–8.

    Article  PubMed  Google Scholar 

  161. Russo RA, Katsicas MM. Clinical remission in patients with systemic juvenile idiopathic arthritis treated with anti-tumor necrosis factor agents. J Rheumatol. 2009;38:1078–82.

    Article  Google Scholar 

  162. Lovell DJ, Reiff A, Ilowite NT, Wallace CA, Chon Y, Lin SL, et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 2008;58:1496–504.

    Article  CAS  PubMed  Google Scholar 

  163. Verbsky JW, White AJ. Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy-resistant systemic onset juvenile rheumatoid arthritis. J Rheumatol. 2004;31:2071–5.

    PubMed  Google Scholar 

  164. Ohlsson V, Balldam E, Foster H, Jandial S, Pain C, Strike H, et al. Anakinra treatment for systemic onset juvenile idiopathic arthritis (SOJIA). Rheumatology (Oxford). 2008;47:555–6.

    Article  CAS  Google Scholar 

  165. Lequerre T, Quartier P, Rosellini D, Alaoui F, De Bandt M, Mejjad O, et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis. 2008;67:302–8.

    Article  CAS  PubMed  Google Scholar 

  166. Zeft A, Hollister R, LaFleur B, Sampath P, Soep J, McNally B, et al. Anakinra for systemic juvenile arthritis: the Rocky Mountain experience. J Clin Rheumatol. 2009;15:161–4.

    Article  PubMed  Google Scholar 

  167. Quartier P, Allantaz F, Cimaz R, Pillet P, Messiaen C, Bardin C, et al. A multicenter, randomized, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis. 2011;70:747–54.

    Article  CAS  PubMed  Google Scholar 

  168. Pardeo M, Marafon DP, Insalaco A, Bracaglia C, Nicolai R, Messia V, et al. Anakinra in systemic juvenile idiopathic arthritis: a single-center experience. J Rheumatol. 2015;42:1523–7.

    Article  CAS  PubMed  Google Scholar 

  169. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997;40:1202–9.

    Article  CAS  PubMed  Google Scholar 

  170. Miettunen PM, Narendran A, Javanthan A, Behrens EM, Cron RQ. Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients. Rheumatology (Oxford). 2011;50:417–9.

    Article  CAS  Google Scholar 

  171. Canna S, Frankovich J, Higgins G, Narkewicz MR, Nash SR, Hollister JR, et al. Acute hepatitis in three patients with systemic juvenile idiopathic arthritis taking interleukin-1 receptor antagonist. Pediatr Rheum. 2009;7:21.

    Article  Google Scholar 

  172. Ruperto N, Quartier P, Wulffraat N, Woo P, Ravelli A, Mouy R, et al. A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum. 2012;64:557–67.

    Article  CAS  PubMed  Google Scholar 

  173. Brachat AH, Grom AA, Wulffraat N, Brunner HI, Quartier P, Brik R, et al. Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy. Arthritis Res Ther. 2017;19:13.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  174. Lovell DJ, Giannini EH, Reiff AO, Kimura Y, Li S, Hashkes PJ, et al. Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis. Arthritis Rheum. 2013;65:2486–96.

    Article  CAS  PubMed  Google Scholar 

  175. Ilowite NT, Prather K, Lokhnuyina Y, Schanberg LE, Elder M, Milojevic D, et al. Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis. Arthritis Rheum. 2014;66:2570–9.

    Article  CAS  Google Scholar 

  176. De Benedetti F, Brunner H, Ruperto N, Kenwright A, Wright S, Calvo I, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;67:2385–95.

    Article  CAS  Google Scholar 

  177. De Benedetti F, Brunner H, Ruperto N, Schneider R, Xavier R, Allen R, et al. Catch-up growth during tocilizumab therapy for systemic juvenile idiopathic arthritis. Results from a phase III trial. Arthritis Rheum. 2015;67:840–8.

    Article  CAS  Google Scholar 

  178. Yokota S, Itoh Y, Morio T, Origasa H, Sumitomo N, Tomobe M, et al. Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan. Ann Rheum Dis. 2016;75:1654–60.

    Article  CAS  PubMed  Google Scholar 

  179. Horneff G, Schulz AC, Klotsche J, Hospach A, Minden K, Foeldvari I, et al. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry. Arthritis Res Ther. 2017;19(1):256.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  180. Simonini G, Ferrara G, Pontikaki I, Scoccimarro E, Giani T, Taddio A, et al. Flares after withdrawal of biologic therapies in juvenile idiopathic arthritis: clinical and laboratory correlates of remission duration. Arthritis Care Res (Hoboken). 2017; https://doi.org/10.1002/acr.23435.

    Article  Google Scholar 

  181. Ringold S, Weiss PF, Beukelman T, DeWitt EM, Ilowite NT, Kimura Y, et al. 2013 Update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Care Res. 2013;65:1551–63.

    Article  Google Scholar 

  182. Kimura Y, DeWitt EM, Beukelman T, Stoll ML, Nigrovic PA, Onel K, et al. Adding canakinumab to the childhood arthritis and rheumatology research alliance consensus treatment plans for systemic juvenile idiopathic arthritis [Letter]. Arthritis Care Res. 2014;66:1430–1.

    Article  CAS  Google Scholar 

  183. Woerner A, Uettwiller F, Melki I, Mouy R, Wouters C, Bader-Meunier B, et al. Biological treatment in systemic juvenile idiopathic arthritis: achievement of inactive disease or clinical remission on a first, second or third biological agent. RMD Open. 2015;1:e000036.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  184. Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Pérez N, Silva CA, et al. Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum. 2010;62(6):1792–802.

    Article  CAS  PubMed  Google Scholar 

  185. Record JL, Beukelman T, Cron RQ. Combination therapy of abatacept and anakinra in children with refractory systemic juvenile idiopathic arthritis: a retrospective case series. J Rheumatol. 2011;38:180–1.

    Article  PubMed  Google Scholar 

  186. Lee M, Isaacs J. The novel use of combined IL-1 and IL-6 inhibition in a patient with severe, aggressive, erosive, systemic-onset juvenile idiopathic arthritis. Eur J Rheumatol. 2017;4:68–9.

    Article  PubMed  PubMed Central  Google Scholar 

  187. de Kleer I, Vastert B, Klein M, Teklenburg G, Arkesteijn G, Yung GP, et al. Autologous stem cell transplantation for autoimmunity induces immunologic self-tolerance by reprogramming autoreactive T cells and restoring the CD4+CD25+ immune regulatory network. Blood. 2006;107(4):1696–702.

    Article  PubMed  CAS  Google Scholar 

  188. Brinkman BMC, de Kleer M, ten Cate R, van Rossum MA, Bekkering WP, Fasth A, et al. Autologous stem cell transplantation in children with severe progressive systemic or polyarticular juvenile idiopathic arthritis. Arthritis Rheum. 2007;56:2410–21.

    Article  CAS  PubMed  Google Scholar 

  189. Swart JF, Wulffraat NM. Mesenchymal stromal cells for treatment of arthritis. Best Pract Res Clin Rheumatol. 2014;28(4):589–603.

    Article  CAS  PubMed  Google Scholar 

  190. Wang L, Zhang Y, Li H, Hong J, Chen X, Li M, et al. Clinical observation of employment of umbilical cord-derived mesenchymal stem cell for juvenile idiopathic arthritis therapy. Stem Cells Int. 2016;2016:9165267.

    PubMed  Google Scholar 

  191. Das R, Guan P, Sprague L, Verbist K, Tedrick P, An Q, et al. Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis. Blood. 2016;127(13):1666–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  192. Gabay C, Fautrel B, Rech J, Spertini F, Feist E, Kötter I, et al. Open-label, multicenter, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still’s disease. Ann Rheum Dis. 2018;77:840–7.

    CAS  PubMed  Google Scholar 

  193. Ravelli A, De Benedetti F, Viola S, Martini A. Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine. J Pediatr. 1996;128:275–8.

    Article  CAS  PubMed  Google Scholar 

  194. Henter JI, Samuelsson-Horne A, Aricò M, Egeler RM, Elinder G, Filipovich AH, et al. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood. 2002;100(7):2367–73.

    Article  CAS  PubMed  Google Scholar 

  195. Ravelli A, Grom AA, Behrens EM, Cron RQ. Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. Genes Immun. 2012;13:289–98.

    Article  CAS  PubMed  Google Scholar 

  196. Braccaglia C, Gatto A, Pardeo M, Lapeyre G, Ferlin W, Nelson R, et al. Anti interferon-gamma (IFN-γ) monoclonal antibody treatment in a patient carrying an NLRC4 mutation and severe hemophagocytic lymphohistiocytosis. Pediatr Rheumatol Online J. 2015; 13(Suppl 1). https://doi.org/10.1186/1546-0096-13-S1-O68.

  197. Canna SW, Girard C, Malle L, de Jesus A, Romberg N, Kelsen J, et al. Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition. J Allergy Clin Immunol. 2017;139(5):1698–701.

    Article  CAS  PubMed  Google Scholar 

  198. Nigrovic PA, White PH. Care of the adult with juvenile rheumatoid arthritis. Arthritis Rheum. 2006;15(55):208–16.

    Article  Google Scholar 

  199. Minden K. Adult outcomes of patients with juvenile idiopathic arthritis. Horm Res. 2009;72(Suppl 1):20–5.

    Article  CAS  PubMed  Google Scholar 

  200. Lomater C, Gerloni V, Gattinara M, Mazzotti J, Cimaz R, Fantini F. Systemic onset juvenile idiopathic arthritis: a retrospective study of 80 consecutive patients followed for 10 years. J Rheumatol. 2000;27:491–6.

    CAS  PubMed  Google Scholar 

  201. Singh-Grewal D, Schneider R, Bayer N, Feldman BM. Predictors of disease course and remission in systemic juvenile idiopathic arthritis: significance of early clinical and laboratory features. Arthritis Rheum. 2006;54:1595–601.

    Article  CAS  PubMed  Google Scholar 

  202. Susic GZ, Stojanovic RM, Pejnovic NN, Damjanov NS, Soldatovic II, Jablanovic DB, Sefik Bukilica MN. Analysis of disease activity, functional disability and articular damage in patients with juvenile idiopathic arthritis: a prospective outcome study. Clin Exp Rheumatol. 2011;29(2):337–44.

    CAS  PubMed  Google Scholar 

  203. Magni-Manzoni S, Pistorio A, Labo E, Viola S, Garcia-Munitis P, Panigada S, et al. A longitudinal analysis of physical functional disability over the course of juvenile idiopathic arthritis. Ann Rheum Dis. 2008;67:1159–64.

    Article  CAS  PubMed  Google Scholar 

  204. Schneider R, Lang BA, Reilly BJ, Laxer RM, Silverman ED, Ibanez D, et al. Prognostic indicators of joint destruction in systemic onset juvenile rheumatoid arthritis. J Pediatr. 1992;120:200–5.

    Article  CAS  PubMed  Google Scholar 

  205. Spiegel LR, Schneider R, Lang BA, Birdi N, Silverman ED, Laxer RM, et al. Early predictors of poor functional outcome in systemic-onset juvenile rheumatoid arthritis. A multicenter cohort study. Arthritis Rheum. 2000;43:2402–9.

    Article  CAS  PubMed  Google Scholar 

  206. Modesto C, Woo P, García-Consuegra J, Merino R, García-Granero M, Arnal C, et al. Systemic onset juvenile chronic arthritis: polyarticular pattern and hip involvement as markers for a bad prognosis. Clin Exp Rheumatol. 2001;19:211–7.

    CAS  PubMed  Google Scholar 

  207. Magni-Manzoni S, Rossi F, Pistorio A, Temporini F, Viola S, Beluffi G, et al. Prognostic factors for radiographic progression, radiographic damage, and disability in juvenile idiopathic arthritis. Arthritis Rheum. 2003;48:3509–17.

    Article  PubMed  Google Scholar 

  208. Oen K, Malleson PN, Cabral DA, Rosenberg AM, Petty RE, Reed M, et al. Early predictors of long-term outcome in patients with juvenile rheumatoid arthritis: subset-specific correlations. J Rheumatol. 2003;30:585–93.

    PubMed  Google Scholar 

  209. Viola S, Felici E, Magni-Manzoni S, Pistorio A, Buoncompagni A, Ruperto N, et al. Development and validation of a clinical index for assessment of long-term damage in juvenile idiopathic arthritis. Arthritis Rheum. 2005;52:2092–102.

    Article  PubMed  Google Scholar 

  210. Sandborg C, Holmes TH, Lee T, Biederman K, Bloch DA, Emery H, et al. Candidate early predictors for progression to joint damage in systemic juvenile idiopathic arthritis. J Rheumatol. 2006;33:2322–9.

    PubMed  Google Scholar 

  211. Wallace CA, Huang B, Bandeira M, Ravelli A, Giannini EH. Patterns of clinical remission in select categories of juvenile idiopathic arthritis. Arthritis Rheum. 2005;52:3554–62.

    Article  PubMed  Google Scholar 

  212. Guzman J, Oen K, Tucker LB, Huber AM, Shiff N, Boire G, et al. The outcomes of juvenile idiopathic arthritis in children managed with contemporary cohort treatments: results from the ReACCh-Out. Ann Rheum Dis. 2015;74:1854–60.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service of Immunology & Rheumatology, Hospital de Pediatría Prof. Dr. Juan P. Garrahan, Buenos Aires, Argentina

    María Martha Katsicas & Ricardo A. G. Russo

Authors
  1. María Martha Katsicas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ricardo A. G. Russo
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Clinical Sciences and Community Health, University of Milano, Milano, Italy

    Rolando Cimaz

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Katsicas, M.M., Russo, R.A.G. (2020). Systemic-Onset Juvenile Idiopathic Arthritis. In: Cimaz, R. (eds) Periodic and Non-Periodic Fevers. Rare Diseases of the Immune System. Springer, Cham. https://doi.org/10.1007/978-3-030-19055-2_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-19055-2_5

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-19054-5

  • Online ISBN: 978-3-030-19055-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation